Ameriprise Financial Inc Uni Qure N.V. Transaction History

Ameriprise Financial Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ameriprise Financial Inc transactions in Uni Qure N.V. stock. As of the latest transaction made, Ameriprise Financial Inc holds 865,798 shares of QURE stock, worth $14.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
865,798
Previous 851,070 1.73%
Holding current value
$14.7 Million
Previous $3.81 Million 11.96%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.78 - $10.12 $55,671 - $149,047
14,728 Added 1.73%
865,798 $4.27 Million
Q2 2024

Aug 14, 2024
BUY
$4.39 - $5.43 $621,777 - $769,078
141,635 Added 19.96%
851,070 $3.81 Million
Q1 2024

May 15, 2024
SELL
$4.82 - $6.93 $534,176 - $768,017
-110,825 Reduced 13.51%
709,435 $3.69 Million
Q4 2023

Feb 14, 2024
BUY
$5.63 - $8.27 $2.51 Million - $3.69 Million
445,795 Added 119.05%
820,260 $5.55 Million
Q3 2023

Nov 14, 2023
SELL
$6.71 - $11.83 $193,053 - $340,360
-28,771 Reduced 7.14%
374,465 $2.51 Million
Q2 2023

Aug 14, 2023
SELL
$11.12 - $22.2 $401,020 - $800,598
-36,063 Reduced 8.21%
403,236 $4.62 Million
Q1 2023

May 15, 2023
SELL
$18.7 - $23.07 $298,863 - $368,704
-15,982 Reduced 3.51%
439,299 $8.85 Million
Q4 2022

Feb 14, 2023
SELL
$18.12 - $27.32 $903,898 - $1.36 Million
-49,884 Reduced 9.87%
455,281 $10.3 Million
Q3 2022

Nov 14, 2022
BUY
$16.98 - $25.54 $440,070 - $661,920
25,917 Added 5.41%
505,165 $9.48 Million
Q2 2022

Aug 15, 2022
SELL
$13.15 - $20.45 $110,078 - $171,186
-8,371 Reduced 1.72%
479,248 $8.93 Million
Q1 2022

May 16, 2022
BUY
$14.54 - $21.5 $4.82 Million - $7.13 Million
331,509 Added 212.36%
487,619 $8.81 Million
Q4 2021

Feb 14, 2022
SELL
$20.24 - $36.01 $7 Million - $12.5 Million
-345,891 Reduced 68.9%
156,110 $3.24 Million
Q3 2021

Nov 15, 2021
BUY
$26.01 - $38.22 $7.22 Million - $10.6 Million
277,610 Added 123.72%
502,001 $16.1 Million
Q2 2021

Aug 16, 2021
SELL
$29.97 - $37.17 $25,144 - $31,185
-839 Reduced 0.37%
224,391 $6.91 Million
Q1 2021

May 17, 2021
SELL
$29.24 - $42.03 $5.06 Million - $7.27 Million
-173,048 Reduced 43.45%
225,230 $7.59 Million
Q4 2020

Feb 12, 2021
BUY
$35.35 - $50.67 $9.43 Million - $13.5 Million
266,718 Added 202.73%
398,278 $14.4 Million
Q3 2020

Nov 16, 2020
SELL
$35.98 - $47.66 $17,414 - $23,067
-484 Reduced 0.37%
131,560 $4.85 Million
Q2 2020

Aug 14, 2020
BUY
$45.06 - $67.74 $2.32 Million - $3.49 Million
51,535 Added 64.01%
132,044 $5.95 Million
Q1 2020

May 15, 2020
BUY
$40.01 - $73.97 $242,180 - $447,740
6,053 Added 8.13%
80,509 $3.82 Million
Q4 2019

Feb 14, 2020
BUY
$37.13 - $74.62 $704,318 - $1.42 Million
18,969 Added 34.19%
74,456 $5.34 Million
Q3 2019

Nov 14, 2019
SELL
$39.36 - $76.8 $442,681 - $863,769
-11,247 Reduced 16.85%
55,487 $2.18 Million
Q2 2019

Aug 14, 2019
SELL
$52.76 - $82.19 $1.18 Million - $1.83 Million
-22,313 Reduced 25.06%
66,734 $5.21 Million
Q1 2019

May 15, 2019
SELL
$27.39 - $68.41 $1.31 Million - $3.28 Million
-47,895 Reduced 34.97%
89,047 $5.31 Million
Q4 2018

Feb 14, 2019
SELL
$22.8 - $33.93 $327,294 - $487,065
-14,355 Reduced 9.49%
136,942 $3.95 Million
Q3 2018

Nov 14, 2018
BUY
$29.75 - $43.08 $107,903 - $156,251
3,627 Added 2.46%
151,297 $5.51 Million
Q2 2018

Aug 14, 2018
BUY
$21.96 - $39.94 $2.13 Million - $3.87 Million
96,929 Added 191.03%
147,670 $5.58 Million
Q1 2018

May 15, 2018
SELL
$17.1 - $26.61 $304,875 - $474,429
-17,829 Reduced 26.0%
50,741 $1.19 Million
Q4 2017

Feb 12, 2018
BUY
$9.47 - $19.59 $649,357 - $1.34 Million
68,570
68,570 $1.34 Million

Others Institutions Holding QURE

# of Institutions
154
Shares Held
41M
Call Options Held
925K
Put Options Held
617K
View Full List

About uniQure N.V.

QURE Quotes by TradingView
  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $793M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email